Vinorelbine (Navelbine®) in the treatment of non-small-cell lung cancer: Studies with single-agent therapy and in combination with cisplatin

R. Gralla, P. Harper, S. Johnson, F. M. Delgado

Research output: Contribution to journalArticle

16 Scopus citations


Initial studies of vinorelbine (Navelbine®) given as a single agent to patients with operable non-small-cell lung cancer (NSCLC) showed that overall response rates of the order of 30% could be obtained with a schedule of 30 mg/m2 given weekly. Although such high levels of response have seldom been obtained when vinorelbine is given alone in one arm of a comparative study, the level of activity is clearly worthwhile and represents a significant improvement over supportive care. Combination therapy with cisplatin has been highly successful, establishing Vinorelbine as a safe well-tolerated agent which provides considerable activity, and experience from large phase III studies suggests that the combination of vinorelbine and cisplatin could represent a reference schedule against which other therapy should be compared.

Original languageEnglish (US)
Pages (from-to)S41-S45
JournalAnnals of Oncology
Issue numberSUPPL. 5
Publication statusPublished - Jan 1 1999



  • Cisplatin
  • Non-small-cell lung cancer
  • Vinorelbine

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this